• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation

    5/15/26 1:00:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples
    Get the next $MED alert in real time by email
    • Body composition, specifically visceral fat levels and lean mass, plays a meaningful role in long-term metabolic health (Serra MC, et al., 2019)
    • Structured plans, habit building, and dedicated coach support work together to produce body composition outcomes that reflect the quality of weight loss, not just its quantity (Arterburn LM, et al., 2019)
    • High-quality protein, nutrient density, and scientifically developed nutrition, combined with structured plans and habit building, support visceral fat reduction and lean mass preservation during weight loss 
    • Human accountability and coach support can lead to stronger outcomes in sustained behavior change and weight management success (Arterburn LM, et al., 2019)

    BALTIMORE, MD, May 15, 2026 (GLOBE NEWSWIRE) -- The success of weight loss programs is often evaluated by how much weight a person loses in the first few weeks or months, but that narrow focus may not reflect what clinical research shows about long-term success. OPTAVIA, a science-backed, coach-guided comprehensive metabolic health system, is among the programs backed by this growing body of evidence. Peer-reviewed research across multiple clinical settings has found that structured meal replacement programs can produce meaningful body composition outcomes, including visceral fat reduction and lean mass preservation (Arterburn LM, et al., 2019). 

    Satya Jonnalagadda, PhD, MBA, RD, Vice President of Scientific & Clinical Affairs at OPTAVIA, says, "Clinical data reveals clear distinctions between weight loss and quality weight loss. Preserving lean mass while reducing visceral fat is what drives sustainable metabolic improvement."

    KEY FACTS:

    • OPTAVIA's clinical approach is supported by 18 randomized controlled trials
    • OPTAVIA's research portfolio includes 30+ scientific research studies and analyses, 40+ peer-reviewed scientific journal publications, and 100+ peer-reviewed scientific presentations and publications

    The Science Behind Structured Programs

    Clinical research has examined structured meal replacement programs across multiple settings, with findings that extend beyond scale weight. A randomized controlled trial published in Obesity Science & Practice found that structured commercial meal replacement programs produced greater reductions in body weight, fat mass, and abdominal fat than a self-directed reduced-calorie approach, concluding that evidence-based commercial programs can be a meaningful tool for adults managing overweight and obesity (Arterburn LM, et al., 2019). 

    A separate multicenter study found that a structured meal replacement plan supported lean mass preservation alongside significant weight reduction, with fat mass representing 80% or more of total weight lost from 12 weeks onward (Coleman CD, et al., 2015). These findings point to body composition, not scale weight alone, as a meaningful measure of what structured programs can produce.

    Body Composition Over the Scale

    Body composition, specifically visceral fat levels and lean mass, plays a meaningful role in metabolic health. Visceral fat acts as a metabolically active organ, releasing inflammatory molecules and hormones that affect insulin sensitivity and overall metabolic function. Reducing it while preserving lean mass is central to what quality weight loss can produce. Research shows that a nutritionally complete, higher-protein structured plan is effective in reducing body fat in the visceral depot, a reduction associated with meaningful cardiometabolic improvement (Serra MC, et al., 2019).

    OPTAVIA's approach centers on nutrient density, high-quality protein, and scientifically developed products, combined with structured plans, habit building, and dedicated coach support with clinical outcomes that reflect that focus.

    The body composition outcomes from OPTAVIA's Optimal Weight 5 & 1 Plan® are clinically proven. Participants achieved a 14% reduction in visceral fat over 16 weeks while retaining 98% of lean mass (Arterburn LM, et al., 2019).

    Why Coaching Changes the Clinical Picture

    Clinical data from OPTAVIA's Optimal Weight 5 & 1 Plan® found that participants working with a coach lose up to 10 times more weight and 17 times more fat than those attempting weight loss independently (Arterburn LM, et al., 2019). That difference reflects what behavioral science suggests about accountability and human support in sustained behavior change and speaks directly to the quality of outcomes the program is designed to produce. 

    "What we see consistently in the research is that accountability changes outcomes, especially when it's personal and one-on-one. A coach addresses the behavioral and emotional patterns that can help drive long-term success," says Jonnalagadda.

    The Metabolic Case for Body Composition 

    Supporting long-term metabolic health requires targeting visceral fat reduction and lean mass preservation, not scale weight alone.  

    OPTAVIA's Optimal Weight 5 & 1 Plan® is built around nutrient density, high-quality protein, and portion control delivered through scientifically developed, convenient products and a structured plan designed to make healthy eating more sustainable. When the body doesn't receive adequate protein and nutritional support during weight loss, it may draw from lean tissue instead of fat, which can affect metabolic rate over time. Meanwhile, visceral fat can continue to contribute to declining insulin sensitivity and metabolic dysfunction. 

    A metabolic health approach that prioritizes both visceral fat reduction and lean mass preservation offers a more complete picture of weight loss quality.

    FAQ

    Q: What weight loss programs have the best clinical evidence and coaching support?

    A: Structured meal replacement programs with coach-guided models have built a strong clinical record across peer-reviewed research. OPTAVIA's approach is supported by 18 randomized controlled trials, with outcomes covering body composition, visceral fat reduction, and lean mass preservation, markers that reflect the broader shift toward metabolic health as a standard for evaluating weight loss success.

    Q: How does OPTAVIA's approach support metabolic health beyond weight loss? 

    A: OPTAVIA's comprehensive metabolic health system centers on nutrient density, high-quality protein, and scientifically developed products, combined with structured plans, habit building, and dedicated coach support. Together, these elements are designed to support visceral fat reduction and lean mass preservation, markers that speak to the quality of weight loss, not just the number on the scale.

    Q: What does clinical evidence show about weight loss coaching?

    A: In OPTAVIA's clinical trial, participants who worked with a coach lost up to 10 times more weight and 17 times more fat than those who attempted weight loss independently (Arterburn LM, et al., 2019). Behavioral science suggests that personal accountability and human support are meaningful factors in sustained behavior change.

    Q: What is visceral fat, and why does it matter more than total weight loss?

    A: Visceral fat is stored deep in the abdomen, surrounding internal organs. Unlike subcutaneous fat, it acts as a metabolically active organ, releasing inflammatory molecules and hormones that affect insulin sensitivity and overall metabolic function. Targeting visceral fat reduction alongside lean mass preservation reflects a more complete picture of weight loss quality.

    * OPTAVIA recommends that you contact your healthcare provider before starting and throughout your weight loss journey. Average weight loss on the Optimal Weight 5 & 1 Plan® is 12 pounds. Clients are in weight loss, on average, for 12 weeks.

    * Arterburn LM, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obesity Science & Practice. 2019.

    https://onlinelibrary.wiley.com/doi/10.1002/osp4.312. In a clinical study, individuals on the OPTAVIA® 5 & 1 Plan® experienced a reduction of 14% visceral fat and 98% of lean mass was retained at 16 weeks. Those on the Optimal Weight 5&1 Plan® with support of an OPTAVIA® Coach successfully lost 10x more weight and 17x more fat than those who tried to lose weight on their own.

    About Medifast

    Medifast (NYSE:MED) is the health and wellness company known for its science-backed, coach-guided lifestyle system. Designed to address the challenges of metabolic dysfunction, the company's holistic approach integrates personalized plans, scientifically developed products and a framework for sustainable habit creation — all supported by a dedicated network of independent coaches.

    Driven to improve metabolic health through advanced science and comprehensive behavioral support, Medifast has introduced Metabolic Synchronization®, a breakthrough science that reverses metabolic dysfunction through targeted metabolic reset. Research demonstrates that the company's comprehensive system activates strong and targeted fat burning to enhance metabolic health and body composition by reducing visceral fat, preserving lean mass and protecting muscle integrity.

    Backed by more than 40 years of clinical heritage, Medifast continues to advance its mission of Lifelong Transformation, Making a Healthy Lifestyle Second Nature®. For more information, visit MedifastInc.com.



    Sarah Evans
    Head of PR, Zen Media
    sarah@zenmedia.com

    Primary Logo

    Get the next $MED alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MED

    DatePrice TargetRatingAnalyst
    11/5/2024$16.50 → $17.00Underperform → Neutral
    DA Davidson
    6/5/2024$25.00 → $17.50Neutral → Underperform
    DA Davidson
    10/13/2023$82.00Equal-Weight
    Stephens
    11/4/2022$278.00 → $106.00Buy → Neutral
    DA Davidson
    8/4/2022$345.00 → $150.00Buy → Hold
    Jefferies
    2/24/2022$349.00 → $341.00Buy
    DA Davidson
    11/8/2021$395.00 → $349.00Buy
    DA Davidson
    More analyst ratings

    $MED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2026

    Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, will announce financial results for the quarter ended June 30, 2026 on Monday, August 3, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Nick Johnson, Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on August 3, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at ht

    7/20/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System

    The leading health and wellness company unveils an evolutionary transformation from weight loss to optimal metabolic health, powered by breakthrough science and human connection Medifast, Inc. (NYSE:MED) today announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The launch also introduces newly formulated meal replacements, including the Trilivy Reset Fueling line enhanced with MetaVantage Technology™, a platform of proprietary ingredient formulas intended to optimize metabolism by unlocking key metabolic pathways. The launch of Trilivy marks a major corporate transformation, and the beginning of a new era focused

    7/17/26 8:30:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management

    Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, two outcomes that standard weight management programs are not designed to address together (Szeliga A, et al., 2026)Women in midlife who focus on scale weight alone may be measuring the wrong thing: visceral fat and lean mass retention are the markers that reflect metabolic progressSleep disruption, elevated stress, and hormonal variability during midlife create conditions where self-directed programs stallThe coaching gap in weight loss outcomes becomes more significant during hormonal transition, when behavioral disruptions make self-directed programs harder to sustain BALTIMORE, MD, June

    6/11/26 7:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schlackman Scott bought $62,950 worth of shares (5,000 units at $12.59), increasing direct ownership by 20% to 30,549 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/12/26 7:10:46 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Chairman & CEO Chard Daniel R bought $5,003 worth of shares (381 units at $13.13) (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    6/17/25 6:20:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Thomas Andrea B bought $3,471 worth of shares (50 units at $68.89), increasing direct ownership by 0.81% to 6,253 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    11/9/23 8:20:19 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: New insider Kiai Parsa claimed ownership of 607,796 shares (SEC Form 3)

    3/A - MEDIFAST INC (0000910329) (Issuer)

    7/10/26 6:47:24 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Director Rose Jeffrey Matthew was granted 18,419 shares (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/28/26 7:34:17 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Director Kiai Parsa was granted 19,317 shares (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/28/26 7:33:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medifast upgraded by DA Davidson with a new price target

    DA Davidson upgraded Medifast from Underperform to Neutral and set a new price target of $17.00 from $16.50 previously

    11/5/24 7:48:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast downgraded by DA Davidson with a new price target

    DA Davidson downgraded Medifast from Neutral to Underperform and set a new price target of $17.50 from $25.00 previously

    6/5/24 7:15:11 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Stephens initiated coverage on Medifast with a new price target

    Stephens initiated coverage of Medifast with a rating of Equal-Weight and set a new price target of $82.00

    10/13/23 7:41:39 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    SEC Filings

    View All

    MEDIFAST INC filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    7/17/26 8:33:58 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    MEDIFAST INC filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    6/1/26 8:59:46 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    MEDIFAST INC filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    5/26/26 4:26:14 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MEDIFAST INC

    SC 13G/A - MEDIFAST INC (0000910329) (Subject)

    7/10/24 1:14:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G filed by MEDIFAST INC

    SC 13G - MEDIFAST INC (0000910329) (Subject)

    7/1/24 4:18:04 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G/A filed by MEDIFAST INC (Amendment)

    SC 13G/A - MEDIFAST INC (0000910329) (Subject)

    2/13/24 10:36:09 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Financials

    Live finance-specific insights

    View All

    Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2026

    Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, will announce financial results for the quarter ended June 30, 2026 on Monday, August 3, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Nick Johnson, Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on August 3, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at ht

    7/20/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast Announces First Quarter 2026 Financial Results

    Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue of $76.0 million, with revenue per active earning coach of $5,432 Independent active earning coaches of 14,000 Net loss of $2.1 million, or $0.19 per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $168.9 million with no debt "We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership

    5/4/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast to Announce Financial Results for the First Quarter Ended March 31, 2026

    Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended March 31, 2026 on Monday, May 4, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on May 4, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or

    4/20/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Leadership Updates

    Live Leadership Updates

    View All

    Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer

    Johnson will succeed Dan Chard as CEO; Chard to remain Chairman of the Board Medifast, Inc. (NYSE:MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain actively engaged as Chairman of the Board, supporting Johnson and the leadership team while continuing to provide strategic oversight. "Nick has been a

    5/26/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast Announces Planned Leadership Transition

     Nicholas Johnson Appointed President, and Expected to Succeed Dan Chard as CEO in June 2026; Chard to Remain Chairman Medifast, Inc. (NYSE:MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Field Operations Officer Nicholas Johnson as President of Medifast, effective immediately. Johnson will work clo

    1/5/26 9:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

    6/7/24 6:09:00 PM ET
    $ADTN
    $ALTR
    $ATNI
    Telecommunications Equipment
    Utilities
    Computer Software: Prepackaged Software
    Technology